D
David C. Montefiori
Researcher at Duke University
Publications - 995
Citations - 79717
David C. Montefiori is an academic researcher from Duke University. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 129, co-authored 920 publications receiving 70049 citations. Previous affiliations of David C. Montefiori include Emory University & University of California, Davis.
Papers
More filters
Journal ArticleDOI
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
Nicole L. Yates,Andrea Stacey,T L Nolen,Nathan Vandergrift,M. A. Moody,David C. Montefiori,Kent J. Weinhold,William A. Blattner,Persephone Borrow,Robin J. Shattock,Myron S. Cohen,Barton F. Haynes,Georgia D. Tomaras +12 more
TL;DR: HIV-1 transmission frequently elicits mucosal HIV-1 envelope-specific IgA responses targeted to gp41 that have a short half-life, and B-cell-activating factor belonging to the TNF family was elevated immediately preceding the appearance of gp41 Abs, likely contributing to an initial T-independent Ab response.
Journal ArticleDOI
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection
Mark G. Lewis,William R. Elkins,Francine E. McCutchan,Raoul E. Benveniste,C.-Y. Lai,David C. Montefiori,Donald S. Burke,Gerald A. Eddy,Avigdor Shafferman +8 more
TL;DR: In vitro neutralization competition assays performed with sera from vaccinated macaques in the presence of the free peptides suggest that of the four conserved envelope peptides of the vaccine, the two originating from gp41 rather than the two from gp120 are responsible for inducing the neutralizing anti-syncytial activity.
Journal ArticleDOI
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection.
Hongshuo Song,Elena E. Giorgi,Vitaly V. Ganusov,Fangping Cai,Gayathri Athreya,Hyejin Yoon,Oana Carja,Bhavna Hora,Peter T. Hraber,Ethan Romero-Severson,Chunlai Jiang,Chunlai Jiang,Xiaojun Li,Shuyi Wang,Hui Li,Jesus F. Salazar-Gonzalez,Maria G. Salazar,Nilu Goonetilleke,Brandon F. Keele,David C. Montefiori,Myron S. Cohen,George M. Shaw,Beatrice H. Hahn,Andrew J. McMichael,Barton F. Haynes,Bette T. Korber,Tanmoy Bhattacharya,Tanmoy Bhattacharya,Feng Gao,Feng Gao +29 more
TL;DR: A computational tool is developed to track recombination in patients, identify recombination hot spots, and show contribution of recombination to antibody escape, which provides insight into molecular mechanisms by which viral recombination contributes to HIV-1 persistence and immunopathogenesis.
Journal ArticleDOI
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Frances Priddy,David J. M. Lewis,Huub C. Gelderblom,Hana Hassanin,Claire Streatfield,Celia C. LaBranche,Jonathan Hare,Josephine H. Cox,Len Dally,Daryl Bendel,David C. Montefiori,Eddy Sayeed,Jim Ackland,Jill Gilmour,Bruce C. Schnepp,J. Fraser Wright,Philip R. Johnson +16 more
TL;DR: A preventive vaccine for HIV is a crucial public health need and adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV.
Journal ArticleDOI
Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins
Gillis R. Otten,Mary Schaefer,Barbara Doe,Hong Liu,Indresh K. Srivastava,Jan zur Megede,Jina Kazzaz,Ying Lian,Manmohan Singh,Mildred Ugozzoli,David C. Montefiori,Mark G. Lewis,David A. Driver,Thomas W. Dubensky,John M. Polo,John J. Donnelly,Derek T. O'Hagan,Susan W. Barnett,Jeffrey B. Ulmer +18 more
TL;DR: PLG microparticles are an effective means of delivering DNA vaccines in nonhuman primates, as demonstrated for two different types of DNA vaccines encoding two different antigens, and are compatible for use with DNA prime-protein boost regimens.